EMA Authorised: NovoMix (insulin aspart) — Novo Nordisk A/S

View source ↗

Summary

NovoMix (insulin aspart) by Novo Nordisk A/S has been authorised for use in the European market for diabetes mellitus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Novomix (insulin aspart protamine/insulin aspart)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus. MAH: Novo Nordisk A/S. Decision date: 22/05/2023